Alembic Pharmaceuticals gets FDA final approval for Paclitaxel Injection USP
Alembic Pharmaceuticals Limited has secured final approval for its abbreviated new drug application (ANDA) for Paclitaxel Injection USP, 30 mg/5 mL (6 mg/mL), 100 mg/16.7 mL (6 mg/mL), and 300 mg/50 mL (6 mg/mL) multiple-dose vials from the US Food & Drug Administration (FDA). According to the Indian pharma company, this is the maiden product […]